Abhay Kadam, MSc

Abhay Kadam is a Medical Anthropologist associated with Johns Hopkins India for 16 years and has 23 years of public health research experience in India. He completed his postgraduation from the Department of Anthropology, Pune University. His final year dissertation was in Forensic Facial Reconstruction, exploring the use of two-dimensional human skull radiographs to build a three-dimensional skull and subsequently a face using the reconstruction method. His key interest areas are mental health, infectious diseases, and digital health.

His work experience mainly comprises research studies funded by NIH, CDC, European Union, and Gates Foundation and conducted in collaboration with international consortium partner universities, Government agencies, National Disease Control Programs, and non-governmental organizations at national, state, and district levels. He has worked in program, monitoring-evaluation, and research which includes intervention studies, behavioral research, qualitative research, behavioral and mHealth technology intervention research, clinical trials, and operational research.

He has worked in a wide range of areas from HIV, TB, malaria, diabetes, and mental health to pharmaceutical regulations, access to medicines, intellectual property rights, hospital-acquired infections, quality improvement initiatives, and antimicrobial resistance. He has experience of conducting research studies among diverse populations like HIV infected/affected individuals, drug-sensitive and drug-resistant TB patients, adolescents infected/affected by HIV, female sex workers, intravenous drug users, and gay/bisexual/transgenders. He has 15 peer-reviewed publications in international journals.

He is currently working as a Study Coordinator for Tuberculosis (TB) Aftermath study and as a Regulatory Coordinator for Dr. D. Y. Patil University study site. TB Aftermath study seeks to provide evidence for an effective and scalable active case finding (ACF) strategy targeting HHs of treated TB cases, a high priority of India’s National Tuberculosis Elimination Program (NTEP).

He worked as a Study Coordinator for the Healthcare-Associated Sepsis study in Neonatal Intensive Care Units (NICU) in Pune, India, supported by the Centre for Disease Control and Prevention (CDC) SHEPheRD Domain 7 program. He worked as a lead Study Coordinator for the implementation of a quality improvement initiative—Comprehensive Unit-based Safety Program (CUSP) to reduce healthcare-associated sepsis in NICUs in Pune, India. He also worked as a Study Coordinator for the study to evaluate the source of early-onset neonatal sepsis due to hospital-acquired pathogens.

He also worked as a Study Coordinator for COMmunity Home Based INDia Prevention of Mother to Child Transmission of HIV (COMBIND PMTCT Study) to enhance the capacity of outreach workers catering to HIV-infected pregnant women for the uptake of PMTCT services using the mHealth platform and motivational counseling. During his initial years, he worked in various positions in PPTCT Clinical trial comparing Six Weeks Extended Nevirapine regime (SWEN) and Single Dose Nevirapine regime (SD) for breastfeeding HIV-reactive mothers.

JHU Studies:

1. Tuberculosis (TB) Aftermath
2. SHEPheRD: Healthcare-Associated Sepsis in the Neonatal Intensive Care Unit in Pune, India
3. SHEPheRD: Implementing the Comprehensive Unit-based Safety Program to Reduce Healthcare-Associated Sepsis in the Neonatal Intensive Care Unit in Pune, India.
4. SHEPheRD: Evaluating the Source of Neonatal Bloodstream Infections due to Classically Hospital Acquired Pathogens in the Neonatal Intensive Care Unit in Pune, India
5. COMmunity Home Based INDia Prevention of Mother to Child Transmission of HIV (COMBIND PMTCT Study)
6. SWEN Study: PPTCT Clinical trial comparing Six Weeks Extended Nevirapine regime (SWEN) and Single Dose Nevirapine regime (SD) for breastfeeding HIV-reactive mothers.

PUBLICATIONS:

1. Cox SR, Kadam A, Atre S, Gupte AN, Sohn H, Gupte N, Sawant T, Mhadeshwar V, Thompson R, Kendall E, Hoffmann C, Suryavanshi N, Kerrigan D, Tripathy S, Kakrani A, Barthwal MS, Mave V, Golub JE; TB Aftermath study team. Tuberculosis (TB) Aftermath: study protocol for a hybrid type I effectiveness-implementation non-inferiority randomized trial in India comparing two active case finding (ACF) strategies among individuals treated for TB and their household contacts. Trials. 2022 Aug 5;23(1):635. doi: 10.1186/s13063-022-06503-6. PMID: 35932062; PMCID: PMC9354295.
2. Johnson J, Latif A, Randive B, Kadam A, Rajput U, Kinikar A, Malshe N, Lalwani S, Parikh TB, Vaidya U, Malwade S, Agarkhedkar S, Curless MS, Coffin SE, Smith RM, Westercamp M, Colantuoni E, Robinson ML, Mave V, Gupta A, Manabe YC, Milstone AM. Implementation of the Comprehensive Unit-Based Safety Program to Improve Infection Prevention and Control Practices in Four Neonatal Intensive Care Units in Pune, India. Front Pediatr. 2022 Jan 6;9:794637. doi: 10.3389/fped.2021.794637. PMID: 35071137; PMCID: PMC8772032.
3. Suryavanshi N, Kadam A, Dhumal G, Nimkar S, Mave V, Gupta A, Cox SR, Gupte N. Mental health and quality of life among healthcare professionals during the COVID-19 pandemic in India. Brain Behav. 2020 Nov;10(11):e01837. doi: 10.1002/brb3.1837. Epub 2020 Sep 11. PMID: 32918403; PMCID: PMC7667343.
4. Suryavanshi N, Kadam A, Gupte N, Hegde A, Kanade S, Sivalenka S, Kumar VS, Gupta A, Bollinger RC, Shankar A, McKenzie-White J, Mave V. A mobile health- facilitated behavioural intervention for community health workers improves exclusive breastfeeding and early infant HIV diagnosis in India: a cluster randomized trial. J Int AIDS Soc. 2020 Jul;23(7):e25555. doi: 10.1002/jia2.25555. PMID: 32618115; PMCID: PMC7332965.
5. Suryavanshi N, Kadam A, Kanade S, Gupte N, Gupta A, Bollinger R, Mave V, Shankar A. Acceptability and feasibility of a behavioral and mobile health intervention (COMBIND) shown to increase uptake of prevention of mother to child transmission (PMTCT) care in India. BMC Public Health. 2020 May 24;20(1):752. doi: 10.1186/s12889-020-08706-5. PMID: 32448299; PMCID: PMC7245843.
6. Johnson J, Robinson ML, Rajput UC, Valvi C, Kinikar A, Parikh TB, Vaidya U, Malwade S, Agarkhedkar S, Randive B, Kadam A, Smith RM, Westercamp M, Mave V, Gupta A, Milstone AM, Manabe YC. High Burden of Bloodstream Infections Associated With Antimicrobial Resistance and Mortality in the Neonatal Intensive Care Unit in Pune, India. Clin Infect Dis. 2021 Jul 15;73(2):271-280. doi: 10.1093/cid/ciaa554. PMID: 32421763; PMCID: PMC8282256.
7. Kadam AB, Atre SR. Negative impact of social media panic during the COVID-19 outbreak in India. J Travel Med. 2020 May 18;27(3):taaa057. doi: 10.1093/jtm/taaa057. PMID: 32307545; PMCID: PMC7188175.
8. Suryavanshi N, Mave V, Kadam A, Kanade S, Sivalenka S, Kumar VS, Harvey P, Gupta R, Hegde A, Gupte N, Gupta A, Bollinger RC, Shankar A. Challenges and opportunities for outreach workers in the Prevention of Mother to Child Transmission of HIV (PMTCT) program in India. PLoS One. 2018 Sep 4;13(9):e0203425. doi: 10.1371/journal.pone.0203425. PMID: 30180186; PMCID: PMC6122806.
9. Millard C, Kadam AB, Mahajan R, Pollock AM, Brhlikova P. Availability of brands of six essential medicines in 124 pharmacies in Maharashtra. J Glob Health. 2018 Jun;8(1):010402. doi: 10.7189/jogh.08.010402. PMID: 29423188; PMCID: PMC5782832.
10. McGettigan P, Roderick P, Kadam A, Pollock A. Threats to global antimicrobial resistance control: Centrally approved and unapproved antibiotic formulations sold in India. Br J Clin Pharmacol. 2019 Jan;85(1):59-70. doi: 10.1111/bcp.13503. Epub 2018 Feb 21. PMID: 29397576; PMCID: PMC6303201.
11. McGettigan P, Roderick P, Kadam A, Pollock AM. Access, Watch, and Reserve antibiotics in India: challenges for WHO stewardship. Lancet Glob Health. 2017 Nov;5(11):e1075-e1076. doi: 10.1016/S2214-109X(17)30365-0. PMID: 29025629.
12. Kadam AB, Maigetter K, Jeffery R, Mistry NF, Weiss MG, Pollock AM. Correcting India's Chronic Shortage of Drug Inspectors to Ensure the Production and Distribution of Safe, High-Quality Medicines. Int J Health Policy Manag. 2016 Sep 1;5(9):535-542. doi: 10.15171/ijhpm.2016.44. PMID: 27694680; PMCID: PMC5010656.
13. McGettigan P, Roderick P, Mahajan R, Kadam A, Pollock AM. Use of Fixed Dose Combination (FDC) Drugs in India: Central Regulatory Approval and Sales of FDCs Containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Metformin, or Psychotropic Drugs. PLoS Med. 2015 May 12;12(5):e1001826; discussion e1001826. doi: 10.1371/journal.pmed.1001826. PMID: 25965416; PMCID: PMC4428752.
14. Maigetter K, Pollock AM, Kadam A, Ward K, Weiss MG. Pharmacovigilance in India, Uganda and South Africa with reference to WHO's minimum requirements. Int J Health Policy Manag. 2015 Mar 9;4(5):295-305. doi: 10.15171/ijhpm.2015.55. PMID: 25905480; PMCID: PMC4417633.
15. Six Week Extended-Dose Nevirapine (SWEN) Study Team, Bedri A, Gudetta B, Isehak A, Kumbi S, Lulseged S, Mengistu Y, Bhore AV, Bhosale R, Varadhrajan V, Gupte N, Sastry J, Suryavanshi N, Tripathy S, Mmiro F, Mubiru M, Onyango C, Taylor A, Musoke P, Nakabiito C, Abashawl A, Adamu R, Antelman G, Bollinger RC, Bright P, Chaudhary MA, Coberly J, Guay L, Fowler MG, Gupta A, Hassen E, Jackson JB, Moulton LH, Nayak U, Omer SB, Propper L, Ram M, Rexroad V, Ruff AJ, Shankar A, Zwerski S. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet. 2008 Jul 26;372(9635):300-13. doi: 10.1016/S0140-6736(08)61114-9. PMID: 18657709.